Skip to main content
. 2017 May 8;8(30):49757–49772. doi: 10.18632/oncotarget.17693

Figure 7. Increased expression of IRF8 in tumor tissues predicted worse DLBCL patient survival.

Figure 7

A total of 67 DLBCL patients were divided into two groups based on the median relative IOD (3.75) of IRF8 in tumor tissues. (A) and (B) The disease-free survival and overall survival of DLBCL patients were significantly decreased with increased expression of IRF8 in tumor tissues, as shown in Kaplan-Meier survival analysis plots (P=0.042 and P=0.02). Significance was determined using the Log Rank test.